 |
市场调查报告书
商品编码
1490033
急性细菌性皮肤和皮肤结构感染疾病的全球市场：按药物类型、感染类型、给药途径、分销管道和地区Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type, By Infection Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
预计2024年全球急性细菌性皮肤和皮肤结构感染疾病市场规模将达38.425亿美元，2024年至2031年复合年增长率为5.8%，2031年将达到57.017亿美元。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 38.425 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 5.8% | 2031 年金额预测 | 57.017 亿美元 |
图：急性细菌性皮肤和皮肤结构感染疾病的区域比例（%）（2024 年）
急性细菌性皮肤和皮肤结构感染疾病（ABSSSI）是指影响皮肤及周围组织和结构的常见细菌感染疾病，包括主要皮肤脓肿、蜂窝性组织炎以及感染的伤口和溃疡。引起 ABSSSI 的常见细菌包括金黄色葡萄球菌和化脓性链球菌。由于抗生素抗药性的增加以及肥胖、糖尿病和生活方式改变等危险因子的增加，ABSSSI 的全球发生率正在增加。
市场动态：
由于世界老年人口的增加和糖尿病等合併症的增加，ABSSSI 的风险正在增加。根据国际糖尿病联盟的数据，2019年约有4.63亿20岁至79岁的成年人患有糖尿病，预计到2045年这一数字将增加至7亿以上。老年人也更容易受到皮肤和软组织感染疾病。快速的都市化和生活方式的改变损害了免疫健康，进一步增加了全球 ABSSSI 的疾病负担。然而，有关临床试验和药物核准的严格规定可能会阻碍市场成长。新型抗菌剂的持续研究和开发以及先进创伤护理疗法的快速普及为市场带来了利润丰厚的机会。
本研究的主要特点
- 该报告详细分析了全球急性细菌性皮肤和皮肤结构感染疾病市场，包括市场规模（百万美元）和年复合成长率（CAGR%）。。
- 它还强调了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
- 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球急性细菌性皮肤和皮肤结构感染疾病市场的主要企业进行了分析。
- 主要企业包括 Fresenius SE & Co.KGaA、辉瑞公司、Amneal Pharmaceuticals LLC、Intas Pharmaceuticals Ltd.、Cadila Healthcare Ltd.、Glenmark Pharmaceuticals Ltd.、GSK plc、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.、AbbVie、GSK plc、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.、AbbVie、 Inc. 、Melinta Therapeutics, Inc.、Accord Healthcare Ltd.、Merck &Co, Inc.、Teva Pharmaceutical Industries Ltd.、Partek Pharmaceuticals, Inc. 等。
- 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球急性细菌性皮肤和皮肤结构感染疾病市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过用于分析全球急性细菌性皮肤和皮肤结构感染疾病市场的各种策略矩阵来促进决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 机会
- 影响分析
- 市场趋势
- 主要进展
- 监管场景
- 製造商收益
- 采用非侵入式感测器技术
- 收购和合作场景
- 产品发布/核准
- 资金筹措和投资
- PEST分析
- 波特的分析
第四章全球急性细菌性皮肤和皮肤结构感染疾病市场 - COVID-19 的影响
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第五章全球急性细菌性皮肤和皮肤结构感染疾病市场：按药物类型，2019-2031（百万美元）
- 口服/肠胃外抗生素
- 奥利万星
- 德拉沙星
- 万古霉素
- 其他的
- 局部抗生素
- 过氧化氢
- 夫西地酸
- 莫匹罗星
- 瑞他帕林
第六章全球急性细菌性皮肤和皮肤结构感染疾病市场：按感染类型，2019-2031（百万美元）
- 医院获得性 ABSSSI
- 社区型 ABSSSI
第七章 全球急性细菌性皮肤和皮肤结构感染疾病市场：按给药途径，2019-2031 年（百万美元）
- 口服
- 胃肠外的
- 局部的
第八章全球急性细菌性皮肤和皮肤结构感染疾病市场：按分销管道划分，2019-2031（百万美元）
- 医院药房
- 零售药房
- 网路药房
第九章全球急性细菌性皮肤和皮肤结构感染疾病市场：按地区划分，2019-2031（百万美元）
第10章竞争格局
- 公司简介
- Fresenius SE &Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck &Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
第十一章分析师建议
第十二章参考文献与调查方法
简介目录
Product Code: CMI1531
Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 3,842.5 Mn in 2024 and is expected to reach USD 5,701.7 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 3,842.5 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.80% | 2031 Value Projection: | US$ 5,701.7 Mn |
Figure. Acute Bacterial Skin And Skin Structure Infections Marke Share (%), By Region, 2024
Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.
Market Dynamics:
Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2019, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.
Key Features of the Study:
- This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.
Detailed Segmentation-
- By Drug Type:
- Oral & Parenteral Antibiotics
- Oritavancin
- Delafloxacin
- Vancomycin
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- Oral
- Parenteral
- Topical
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Fresenius SE & Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Infection Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Manufacturer Revenue
- Adoption of Non-invasive Sensor Technologies
- Acquisitions and Partnerships Scenario
- Product Launches/Approvals
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral & Parenteral Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Oritavancin
- Delafloxacin
- Vancomycin
- Others
- Topical Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Community Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Topical
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Fresenius SE & Co. KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
- Fresenius SE & Co. KGaA
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
02-2729-4219
+886-2-2729-4219
2024-2032 年医院感染治疗市场报告（按药物类型、适应症和地区）
全球护理点传染病检测市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测
急性细菌性皮肤和结构性感染疾病的全球市场：市场规模、份额、趋势分析、机会、预测，2019-2030
假体关节感染治疗市场，按类型、应用、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测
导管相关血流感染市场：按药物类别、给药途径、适应症、分销管道划分 - 全球预测 2024-2030 年
传染性肠炎治疗市场 - 全球产业规模、份额、趋势、机会和预测，按给药途径（口服、注射）、药物类型（抗生素、抗病毒药物、其他）、地区和竞争细分，2019-2029F
新兴传染病诊断市场 - 全球产业规模、份额、趋势、机会和预测，按应用、技术、感染类型、疾病类型、最终用户、地区和竞争细分，2019-2029F
医院感染治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物类型、应用、地区和竞争细分，2019-2029F
Bowie Dick 测试包市场、占有率、规模、趋势、行业分析报告：依产品类型、应用、地区、细分市场预测，2024-2032年
传染性肠炎治疗市场 - 按药物类型、给药途径、药物类型、配销通路- 全球预测
▼